High Unmet Need and Clinical Significance of Adjuvant Therapy for Pancreatic Cancer

Pancreatic cancer is one of the most aggressive solid tumors, with an overall 5-year survival rate of just over 10%. The current standard of care involves surgical resection followed by multi-agent chemotherapy with curative intent; however, a significant proportion of patients experience recurrence within a few years, resulting in a poor prognosis. The APOLLO Phase 2 clinical trial (NCT04858334), which has now commenced, aims to address this unmet medical need by introducing a new targeted therapy option in the adjuvant therapy setting for pancreatic cancer after surgery. By effectively inhibiting minimal residual disease that may remain after surgery, it may be possible to reduce the recurrence rate and significantly improve the cure rate for pancreatic cancer.

Design and Patient Selection Criteria for the APOLLO Clinical Trial

This trial, led by the National Cancer Institute (NCI) and the ECOG-ACRIN Research Group, is characterized by rigorous biomarker-driven patient selection. Only patients with resectable pancreatic cancer who have been confirmed to have a pathogenic mutation in the BRCA1, BRCA2, or PALB2 gene through genetic testing are eligible to participate in the trial. After undergoing surgery and at least 3 months of multi-agent chemotherapy, patients with no evidence of disease progression will be randomized in a 2:1 ratio to receive olaparib (Lynparza) or placebo and will continue treatment for 1 year. The primary endpoint of the trial is disease-free survival (DFS), which will be used to directly compare the effects on recurrence.

Mechanism of PARP Inhibitors and Synergistic Effect of Target Mutations

Olaparib works by inhibiting PARP (Poly ADP-ribose polymerase), an enzyme involved in the repair of DNA single-strand breaks. Cancer cells with BRCA or PALB2 mutations have defects in the homologous recombination repair (HRR) pathway, which is responsible for repairing DNA double-strand breaks. When olaparib is administered, it blocks PARP, causing cancer cells to lose both DNA repair pathways, leading to cell death through a mechanism called synthetic lethality. This approach minimizes toxicity to normal cells while selectively killing mutated tumor cells, making it an effective treatment strategy that can maintain the patient's quality of life and prevent recurrence.

Strategic Collaboration between AstraZeneca and MSD and Market Expansion Potential

Olaparib is a flagship drug that is being co-developed and co-commercialized by AstraZeneca and MSD through a $8.5 billion deal signed in 2017. It has already been approved by the FDA in 2019 as a maintenance therapy for metastatic pancreatic cancer, and if this trial is successful, it will expand the indications to include early-stage adjuvant therapy after surgery, significantly increasing the number of patients who can be treated. With the global market for pancreatic cancer treatments growing rapidly to approximately $3 billion per year, expanding the indications for olaparib will further solidify the companies' market share. In particular, given that competing PARP inhibitors such as rucaparib and niraparib have not yet been approved for adjuvant therapy, there is potential for a first-mover advantage.